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Introduction
Malignant external otitis (MEO) is an aggres-
sive and potentially fatal disease that affects the
external auditory canal (EAC); it can spread
through the fissures of Santorini and the osseous-
cartilaginous junction(1). This rare disorder occurs
almost exclusively in elderly, diabetic patients or
immune-compromised ones(1). Today there is no
data about incidence of MEO. Pseudomonas aerug-
inosa is the most common infectious agent but
other microorganisms such as Staphylococcus
aureus, Staphylococcus epidermidis, Proteus
mirabilis, Klebsiella oxytoca, Klebsiella pneumoni-
ae, Candida albicans and Aspergillus fumigatus
have been associated with MEO(2,3). The infection
may be polymicrobial(4). 
It is thought that microangiopathy in the ear
canal predisposes elderly diabetic patients to
MEO(5). Occurrence in children is rare and associat-
ed with diabetes, anaemia, malnutrition, and
chemotherapy treatment(6). Dermatitis of the EAC,
concurrent medication with antibiotics, recent ear
irrigation are other promoting factors(1).
In this paper, epidemiological and clinical data
of patients affected by MEO and admitted consecu-
tively to our hospital over an 11-year period were
retrospectively evaluated.
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ABSTRACT
Objectives: Malignant external otitis (MEO) is an aggressive and potentially fatal disease that affects the external auditory
canal (EAC); it occurs almost exclusively in elderly, diabetic patients or immune-compromised ones. The aim of this study was to
describe epidemiological and clinical characteristics of a consecutive series of patients affected by malignant external otitis (MEO)
and to conceive a flow-chart for its management.
Material and methods: Adult patients diagnosed with and treated for MEO at the University Hospital of Messina, Italy
between 2003 and 2013 were identified. Charts were reviewed for history, clinical presentation, laboratory data, treatment, and out-
comes. 
Results: Data of 11 patients were analyzed. Patients’ mean age was 67.6 years, and ten were males. All but one suffered from
diabetes and one was HIV infected. Average time of arrival at our department from onset of symptoms was 12.3 weeks. Intravenous
antibiotics were administered in seven cases whereas exclusively oral antibiotics were given to four patients. Local antibiotic therapy
was associated to systemic administration in seven cases. Four patients underwent surgical treatment. The median duration of anti-
biotic treatment was 12.4 weeks. Ten patients experienced a complete recovery even if in one of these residual facial palsy was repor-
ted; one patient died of a skull base osteomyelitis with multiple nerve involvement. A flow-chart which could guide physicians in the
management of MEO is proposed.
Conclusions: Malignant external otitis still remains today a very challenging issue. Randomized clinical trials are needed to
better clarify which medical and surgical treatment could be the gold standard. A consensus diagnostic flow diagram could help in
the management of this pathology.
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Materials and methods
The AOU Policlinico “G. Martino” of
Messina, Italy, is a tertiary-care university hospital
with 650 beds serving a population of about
1,000,000 in eastern Sicily and southern Calabria.
All patients diagnosed with MEO consecutively
from January 2003 through December 2013 were
included in this study. Patient’s clinical histories
were stored in a database that included demograph-
ic characteristics (age, sex), clinical and laboratory
findings recorded on admission and during hospi-
talization, therapeutic interventions, and clinical
outcome.
Diagnosis of MEO was established, as sug-
gested by Cohen(7), in the presence of “obligatory”
criteria (pain, oedema, exudate, granulations,
micro-abscess (when operated), or failure of local
treatment (>1week). The presence of “occasional”
criteria (diabetes, cranial nerve involvement, posi-
tive scan, debilitating condition and old age) alone
was not considered sufficient for diagnosis of
MEO(7).
Dossiers with doubtful diagnosis and incom-
plete clinical data were excluded from the study.
Clinical response was assessed at the end of treat-
ment and was defined as cure or failure in the case
of persistence or worsening of clinical and laborato-
ry findings. Relapse was defined as the reappear-
ance of signs and symptoms of disease after initial
successful treatment. 
Results
In the study period, 11 patients were diag-
nosed with MEO. Admissions averaged one per
year, without any seasonal variation. All patients
had previously been treated in other hospitals or
clinics when they came to our observation. Data
regarding clinical characteristics, therapy and out-
come of these patients are analytically shown in
table 1.
Patients’ mean age was 67.6 years (range, 48-
83 years), and ten were males. Regarding comor-
bidities, 10/11 suffered from diabetes (type 1 in one
case, and type 2 nine cases) with a mean HbA1c of
7.6%. Three diabetic patients were poorly con-
trolled (HbA1c >8%). One patient was HIV infect-
ed.
Two had undergone traumatic maneuvers
before the onset of infection (cleaning of EAC with
ear swab), while one patient underwent extraction
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Table 1: Clinical characteristics, therapy and outcome of 11 patients with Malignant external otitis.
Bid, twice a day; EOT, end of treatment; ND, not done; PO, by mouth; qd, every day; qid, four times a day; tid, three times a day; W,
weeks
of cerumen plug and one patient had performed
thermal therapy previously.
Clinical presentation at the time of admission
All patients presented with unilateral otalgia,
8/11 with otorrhea, 4/11 with initial cranial nerve
lesion (three, facial nerve palsy, one XI-XII nerves
palsy), 3/11 complained of temporo-mandibular
joint (TMJ) symptom, 3/11 with mastoid region
swelling, and one complained of cephalalgia, one
with fever and one with intraparotid lymphadenitis.
Otoscopic examination highlighted granulation tis-
sue in all cases, stenosis of external auditory canal
in 8/11 patients, and polyp in 3/11 cases.
All patients had received systemic antibiotic
therapy before admission: fluoroquinolones in 6/11
cases; cephalosporins in 3/11 cases;
amoxicillin/clavulanic acid in one case. In 2/11
cases tobramycin drops had been administered
locally. Average time of referral to our department
after the beginning of first cycle of therapy was
12.3 weeks (range, 4-18 weeks).
Microbiology
In five cases the infection was monomicrobial
and caused by P. aeruginosa, and the remaining six
were polymicrobical: Serratia fonticola and
Serratia marcescens in two cases, P. aeruginosa
and S. epidermidis in two cases, P. aeruginosa and
Proteus mirabilis in two cases. 
Laboratory parameters, Imaging and
Histopathologic examination 
At admission, erythrocyte sedimentation rate
(ESR) mean value was 71.6 mm/h (range 20-177);
mean C-reactive protein (CRP) 4.4 mg/l (range,
0.3-13.6 mg/l); mean white blood cells (WBC)
count 10561 × 109/l (range, 3800-15670).
All patients underwent computed tomography
(CT) scan, five patients underwent magnetic reso-
nance imaging (MRI), and 99mTc-sulesomab
(LeukoScan; Immunomedics Europe, Hillegom,
The Netherlands) scan was performed in three
cases. In all cases, CT scan showed presence of soft
tissue in the EAC. In 9/11 cases an erosion of the
walls of the EAC was highlighted. Other imaging
findings included: mastoid involvement in 5/11
cases, middle ear involvement in 5/11 patients, TMJ
involvement in 3/11 cases, skull base involvement
in 2/11 patients. MRI was performed on the basis of
CT scan findings (mastoid, middle ear, parotid and
skull base involvement). 99mTc-sulesomab scan
revealed an abnormal tracer uptake in the same
areas highlighted by CT scans suggesting a focal
inflammatory/infectious process consistent with
MEO in the three cases in which it was performed. 
Treatment
The first objective of our therapy was the con-
trol of diabetes. Intravenous (IV) antibiotic therapy
was administered in 7/11 cases, associated to oral
(PO) antibiotics in two patients; PO therapy only
was administered in four patients. In 7/11 patients a
local antibiotic therapy was also associated.
Monotherapy with fluoroquinolone was adminis-
tered in 8 cases (PO ciprofloxacin 750 mg bid in
four cases; IV levofloxacin 500 mg bid then IV
ciprofloxacin 400 mg bid in one patient; IV lev-
ofloxacin 500 mg bid in one patient; IV
ciprofloxacin 400 mg bid in two patients). A mul-
tidrug treatment was administered in three cases:
fluoroquinolone + aminoglycoside in one patient;
glycopeptides and cephalosporin in one case. In one
case (infected with multiresistant S. epidermidis
and P. aeruginosa), IV vancomycin 500 mg qid
(followed by PO linezolid 600 mg bid), in combina-
tion with PO ciprofloxacin 750 mg bid were admin-
istered. Cleaning of external auditory canal was
performed in all cases. The median duration of
antibiotic treatment was 12.4 weeks (range, 8-20
weeks).  No adverse effects were observed. 
Two patients underwent biopsy; four patients
underwent surgical treatment (debridement of EAC
in three cases and facial nerve decompression in
one other). No patient received hyperbaric oxygen
therapy. All patients underwent serial suctions of
ear secretion and, if necessary, removal of granula-
tion tissue.
Histological examination was obtained in six
cases, showing granulation tissue in all cases.
Outcome
Ten patients out of 11 experienced complete
clinical recovery even if one patient had a residual
facial palsy. One patient, despite 18 weeks of med-
ical treatment and a surgical debridement, died of
an infective skull base osteomyelitis with multiple
nerve involvement caused by P. aeruginosa and S.
epidermidis. In this case, an initial diagnostic delay
of 16 weeks had been documented. Surgical treat-
ment was carried out in another two patients.
At the end of treatment, mean ESR was 12.5
mm/h, mean CRP value 0.6 mg/l; mean WBC 6778
× 109/l. 
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CT scan at the end of treatment was performed
in all patients (except for patient # 9 who died, and
who had undergone other scans during treatment):
persistent erosion of EAC was documented in 5/11
patients; TMJ involvement was shown in 2/11
cases; only one patient showed a persistent involve-
ment of mastoid and middle ear; one patient pre-
sented signs of erosion of the skull base; the pres-
ence of soft tissue in EAC was revealed in one
patient.
LeukoScan was performed in three patients at
the end of treatment; a reduced tracer uptake in
comparison with previous exam was found in two
patients, and a persistent tracer uptake was found in
one patient. The latter continued medical treatment
until MEO was resolved on the basis of this imag-
ing finding. The remaining 10 patients were fol-
lowed-up for at least six months after the end of
treatment. No recurrences were registered during
follow-up period.
Discussion
Today, clinical management of MEO is still
difficult and full in pitfalls. This is particularly
important as early diagnosis is considered a major
prognostic factor(8-10). We propose a flow-chart
which could guide physicians in the management of
MEO (Figure 1).
In comparison with a previous one(1), our flow-
chart suggests a possible assessment after 6-8
weeks of treatment, highlighting the usefulness of
99m Tc sulesomab. Ear-swab culture may not
always be reflective of the pathogenic organism
infecting the temporal bone in MEO. Tissue biopsy
should be recommend in cases in which there is
poor or no response to ear-swab culture-directed
therapy(11).
In our series, even though the small number of
cases does not allow us to reach statistically signifi-
cant results, prognosis did not seem to be related to
patients’ age; this is in line with some studies(12, 13).
On the contrary, Soudry et al’s results suggested a
lower life expectancy for patients aged 70 years and
older(14). 
In our series, male/female ratio showed a
higher percentage of male patients. Other authors
have registered similar findings(15-17). Explanations
for this higher male incidence are hard to find. Nine
of our patients were affected by diabetes, in line
with some studies which report a prevalence of this
disease in MEO of between 65% and 95%(12, 13, 17).
However, some papers have shown that degree of
glucose intolerance and clinical outcome does not
present a relevant correlation(12, 18). Similarly, HbA1c
levels were altered in just 3/11 of our cases. These
three cases recovered fully with an average duration
of treatment of 11.3 weeks, which was close to the
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Fig. 1: Flow-chart for the management of MEO
general average (12.4 weeks). This finding supports
the thesis of the weakness of this parameter as a
prognostic index for MEO.
In our series, mean diagnostic delay was 12.4
weeks, longer than Loh et al’s(12) results but between
1 and 7 months, as other studies report(19, 20).
Lethality was 1/11 in our series; in the series
reported by Hariga et al (17) this was 0/19; in
Jacobsen et al’s series it was al 2/46(21), and in the
series by Al-Noury et al, 0/18(22). It is believed that
mortality rate for MEO is not related to age, sex,
degree of glucose tolerance, duration of diabetes,
microorganism, comorbid condition, or involve-
ment of a single cranial nerve. Instead, skull base
osteomyelitis, intracranial extension, and involve-
ment of multiple cranial nerves can be considered
negative prognostic indexes(18). The most involved
cranial nerve in our series was the facial nerve, as
other studies reported(1, 23). 
Patients who had poorer outcomes presented a
residual facial palsy in one case and a multiple cra-
nial nerves involvement in one other case. These
findings seem in line with other authors’ experi-
ence(12-14, 18).
Recurrence rate in our series was 0/11. Al-
Noury et al reported a recurrence rate of 3/18(22),
Hariga et al. 3/19(17), and Jacobsen et al. 2/51(21).
A dramatic decrease of post-treatment CRP
and ESR values in comparison with initial values
was found in our series. However, to confirm the
usefulness of these markers in the evaluation of dis-
ease activity serial readings are necessary(12).
Differential diagnosis of MEO includes:
severe external otitis and temporal bone cancer.
Histological examination may be necessary as it is
the only definitive method to distinguish an inva-
sive infection from malignancies(24-26). 
CT findings in our series highlighted the
involvement of EAC in all cases, in line with
Peleg’s work(27). Erosion of the EAC was found in
9/11 patients; two patients did not present with this
finding probably because referral to our department
was more timely (diagnostic delay of 8 weeks in the
first case, and 9 weeks in the second one): deminer-
alization becomes evident after weeks of inflamma-
tion(1), making early disease hard to detect using CT
scan.
Contrary to the observations by Peleg et al(27),
but in line with other authors’ works(12, 28), there was
no correlation between the presence of major area
involvement (TMJ, skull base, parotid space, etc)
and poor outcome in our series.
CT scans at follow-up showed some persistent
changes in clinically recovered patients, in line with
other authors’ experience(22). These outcomes rein-
forced the following concept: once demineraliza-
tion has occurred, bony changes persist even after
inflammation has been resolved(1, 29) (Fig. 2). Thus,
CT scan is not reliable in predicting disease activi-
ty(12, 28). To evaluate MEO activity Gallium-67 citrate
(Ga-67) scintigraphy can be used(30). Ga-67 concen-
trates in areas of inflammation by binding directly
to bacteria, and therefore can be used to follow the
resolution of osteomyelitis and assess when antibi-
otic therapy can be stopped(30).
In alternative to this technique, we opted for
the use of Tc-sulesomab scan in three patients. This
method would appear to be quite useful (Fig. 3). It
allowed  identification of a case where the disease
still showed signs of activity thus requiring continu-
ation of antibiotic treatment.
In comparison with 67Ga
scintigraphy, some advantages
can be mentioned for 99mTc-
sulesomab. It shows higher
sensitivity and specificity in
the evaluation of
osteomyelitic processes, such
as diabetic foot(31, 32).
Moreover, radiation dose is
lower (effective dose 5-6
mSv) compared to 67Ga-Citrate (about 10 mSv)(31).
Finally, time of execution for a 99mTc-sulesomab
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Fig. 2: Patient n. 1. Coronal and assial CT scan highligh-
ting an osteitis of the right temporal bone.
Fig. 3: Patient n. 1 “4h (at the top
and in the middle) and 24h (at
the bottom) 99mTc Sulesomab
scans in an under-treatment
patient affected by a MEO of the
right ear. An uptake of the tracer
is highlighted at the level of the
right temporal bone”.
scan is shorter than for a 67Ga scintigraphy (4-24h
vs. 48-72h)(33).
MRI may be useful to show nasopharyngeal,
parapharyngeal, and/or intracranial involvement
and TMJ infiltration(34). In our series, patients who
underwent an MRI scan presented with the involve-
ment of one or more of the above structures, and
this imaging examination was useful to evaluate the
extension of the invasive process.
Another imaging technique that may be used
in patients affected by MEO is Technetium-99m
methyline diphosphonate (Tc-99m-MDP) bone
scintigraphy. Tc-99m-MDP bone scintigraphy can
be used in the initial evaluation of patients with sus-
pected osteomyelitis as it demonstrates alterations
in osteoblastic activity. However, bone scan
remains positive for a long time after successful
treatment of osteomyelitis due to the ongoing
process of bone repair, so it should not be used to
monitor evolution(35-37).  
Fluoroquinolones were the most used antibi-
otics. The antipseudomonal activity of fluoro-
quinolones has made them the treatment of choice,
although a combination of an aminoglycoside and
beta-lactam antibiotic may also be quite effective(1, 38). 
Average treatment duration in surviving
patients of our series was 11.7 weeks. As reported
in literature, treatment should be continued for at
least 4 weeks, but the duration of therapy can be
modified on the basis of clinical course, ESR, CRP
and imaging findings(38). Hyperbaric oxygen has
been used with contrasting results by several
authors and may be considered as an adjuvant treat-
ment for refractory cases although efficacy remains
doubtful(39-42).
Today, extensive surgical debridement is no
longer considered the gold standard treatment and
has been replaced by minimally invasive debride-
ment associated with long-term antimicrobial
chemotherapy(23, 27). Further extension of the opera-
tion may promote the spread of infection to healthy
bone(43). Four patients of our series underwent
surgery and two resulted in poor outcome, support-
ing the above considerations.
Conclusion 
MEO still remains today a very challenging
issue. Randomized clinical trials are needed to bet-
ter clarify which medical and surgical treatment
could be the gold standard. A consensus diagnostic
flow diagram could help in the management of this
pathology. The role of 99mTc-sulesomab as a rapid,
effective and safe imaging agent for treatment eval-
uation and follow-up of patients with MEO
deserves to be investigated. 
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